{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:38:27Z","timestamp":1791459507522,"version":"4.3.4"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"Importance<\/jats:title>Antidepressant use during pregnancy has been associated with neurodevelopmental disorders in children in some studies. However, results may be explained by uncontrolled confounding by parental mental health status, genetics, and environmental factors.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the association between antidepressant use in pregnancy and neurodevelopmental outcomes in children.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study of health care utilization data was separated into cohorts of publicly and privately insured pregnant individuals and their children nested in the Medicaid Analytic eXtract (MAX; 2000-2014) and the IBM MarketScan Research Database (MarketScan; 2003-2015). A total of 1.93 million pregnancies in MAX and 1.25 million pregnancies in MarketScan were recorded. Children were followed from birth until outcome diagnosis, disenrollment, death, or end of study (maximum 14 years). Analyses were conducted between August 2020 and July 2021.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Dispensing of antidepressant medication from gestational week 19 until delivery, the period of synaptogenesis.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Neurodevelopmental disorders in children defined using validated algorithms. Early pregnancy exposure was considered in sensitivity analyses, and approaches to confounding adjustment included propensity score fine stratification, discontinuers comparison, and sibling analyses.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the individuals included in the analysis, there were 145\u202f702 antidepressant-exposed and 3\u202f032\u202f745 unexposed pregnancies; the mean (SD) age among the antidepressant exposed and unexposed was 26.2 (5.7) and 24.3 (5.8) years in MAX and 32.7 (4.6) and 31.9 (4.6) years in MarketScan, respectively; and in MAX, which collected information on race and ethnicity, 72.4% of the antidepressant-exposed and 37.1% of the unexposed individuals were White. Crude results suggested up to a doubling in risk of neurodevelopmental outcomes associated with antidepressant exposure; however, no association was observed in the most fully adjusted analyses. When comparing antidepressant-exposed and unexposed siblings, hazard ratios were 0.97 (95% CI, 0.88-1.06) for any neurodevelopmental disorder, 0.86 (95% CI, 0.60-1.23) for autism spectrum disorder, 0.94 (95% CI, 0.81-1.08) for attention-deficit\/hyperactivity disorder, 0.77 (95% CI, 0.42-1.39) for specific learning disorders, 1.01 (95% CI, 0.88-1.16) for developmental speech\/language disorder, 0.79 (95% CI, 0.54-1.17) for developmental coordination disorder, 1.00 (95% CI, 0.45-2.22) for intellectual disability, and 0.95 (95% CI, 0.80-1.12) for behavioral disorders. Results were generally consistent for antidepressant classes and drugs and across exposure windows.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this cohort study suggest that antidepressant use in pregnancy itself does not increase the risk of neurodevelopmental disorders in children. However, given strong crude associations, antidepressant exposure in pregnancy may be an important marker for the need of early screening and intervention.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2022.4268","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T15:01:46Z","timestamp":1664809306000},"page":"1149","source":"Crossref","is-referenced-by-count":97,"title":["Association of Antidepressant Use During Pregnancy With Risk of Neurodevelopmental Disorders in Children"],"prefix":"10.1001","volume":"182","author":[{"given":"Elizabeth A.","family":"Suarez","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreen","family":"Straub","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Wisner","sequence":"additional","affiliation":[{"name":"Asher Center for the Study and Treatment of Depressive Disorders, Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page B.","family":"Pennell","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Lester","sequence":"additional","affiliation":[{"name":"Center for the Study of Children at Risk, Departments of Psychiatry and Pediatrics, Warren Alpert Medical School of Brown University, Women and Infants Hospital, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Lurie Center for Autism, Massachusetts General Hospital, Lexington"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mogun","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F.","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"ioi220056r1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00737-015-0593-1","article-title":"Estimated prevalence of antenatal depression in the US population.","volume":"19","author":"Ashley","year":"2016","journal-title":"Arch Womens Ment Health"},{"issue":"8","key":"ioi220056r2","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1089\/jwh.2011.3466","article-title":"Depression and treatment among U.S. pregnant and nonpregnant women of reproductive age, 2005-2009.","volume":"21","author":"Ko","year":"2012","journal-title":"J Womens Health (Larchmt)"},{"issue":"6","key":"ioi220056r3","doi-asserted-by":"publisher","first-page":"542.e1","DOI":"10.1016\/j.ajog.2010.07.007","article-title":"Mental health and access to services among US women of reproductive age.","volume":"203","author":"Farr","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"ioi220056r4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.genhosppsych.2012.12.010","article-title":"National trends in antidepressant medication treatment among publicly insured pregnant women.","volume":"35","author":"Huybrechts","year":"2013","journal-title":"Gen Hosp Psychiatry"},{"issue":"11","key":"ioi220056r5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/bdra.v106.11","article-title":"Using insurance claims data to identify and estimate critical periods in pregnancy: an application to antidepressants.","volume":"106","author":"Ailes","year":"2016","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"ioi220056r6","doi-asserted-by":"publisher","first-page":"194.e1","DOI":"10.1016\/j.ajog.2007.07.036","article-title":"Use of antidepressant medications during pregnancy: a multisite study.","volume":"198","author":"Andrade","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"ioi220056r7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jad.2019.12.014","article-title":"The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability.","volume":"264","author":"Molenaar","year":"2020","journal-title":"J Affect Disord"},{"issue":"2","key":"ioi220056r8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/jcph.v61.2","article-title":"Neonatal and childhood outcomes in offspring of pregnant women using antidepressant medications: a critical review of current meta-analyses.","volume":"61","author":"Uguz","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"ioi220056r9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-017-0993-3","article-title":"Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations.","volume":"16","author":"Morales","year":"2018","journal-title":"BMC Med"},{"issue":"10","key":"ioi220056r10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s00787-014-0558-3","article-title":"Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.","volume":"23","author":"El Marroun","year":"2014","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"2","key":"ioi220056r11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40801-021-00232-z","article-title":"Antidepressant use during pregnancy and the potential risks of motor outcomes and intellectual disabilities in offspring: a systematic review.","volume":"8","author":"Al-Fadel","year":"2021","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"ioi220056r12","doi-asserted-by":"publisher","first-page":"e67405","DOI":"10.1371\/journal.pone.0067405","article-title":"Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations.","volume":"8","author":"Palmsten","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ioi220056r13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent.","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"issue":"4","key":"ioi220056r14","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"6","key":"ioi220056r15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/EDE.0000000000000541","article-title":"Carryover effects in sibling comparison designs.","volume":"27","author":"Sj\u00f6lander","year":"2016","journal-title":"Epidemiology"},{"issue":"2","key":"ioi220056r16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on P values: context, process, and purpose.","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"issue":"5","key":"ioi220056r17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/AOG.0b013e3182a603bb","article-title":"Development of a comorbidity index for use in obstetric patients.","volume":"122","author":"Bateman","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"2","key":"ioi220056r18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamapediatrics.2015.3356","article-title":"Antidepressant use during pregnancy and the risk of autism spectrum disorder in children.","volume":"170","author":"Boukhris","year":"2016","journal-title":"JAMA Pediatr"},{"key":"ioi220056r19","doi-asserted-by":"publisher","first-page":"j3668","DOI":"10.1136\/bmj.j3668","article-title":"Antidepressant use during pregnancy and psychiatric disorders in offspring: Danish nationwide register based cohort study.","volume":"358","author":"Liu","year":"2017","journal-title":"BMJ"},{"issue":"15","key":"ioi220056r20","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1001\/jama.2017.3415","article-title":"Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children.","volume":"317","author":"Brown","year":"2017","journal-title":"JAMA"},{"issue":"25","key":"ioi220056r21","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1301449","article-title":"Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism.","volume":"369","author":"Hviid","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi220056r22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaac.2016.02.013","article-title":"Gestational Exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a national register-based study.","volume":"55","author":"Malm","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"15","key":"ioi220056r23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2017.3413","article-title":"Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit\/hyperactivity disorder in offspring.","volume":"317","author":"Sujan","year":"2017","journal-title":"JAMA"},{"issue":"16","key":"ioi220056r24","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1017\/S0033291717001301","article-title":"Autism risk following antidepressant medication during pregnancy.","volume":"47","author":"Viktorin","year":"2017","journal-title":"Psychol Med"},{"key":"ioi220056r25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP","article-title":"Antidepressant exposure in pregnancy and risk of autism spectrum disorders.","volume":"5","author":"S\u00f8rensen","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"1","key":"ioi220056r26","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.190","article-title":"Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study.","volume":"6","author":"Castro","year":"2016","journal-title":"Transl Psychiatry"},{"issue":"12","key":"ioi220056r27","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/bjo.v128.12","article-title":"Attention-deficit\/hyperactivity disorder in children following prenatal exposure to antidepressants: results from the Norwegian Mother, Father and Child Cohort Study.","volume":"128","author":"Lupattelli","year":"2021","journal-title":"BJOG"},{"issue":"6","key":"ioi220056r28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/mp.2014.90","article-title":"Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system.","volume":"20","author":"Clements","year":"2015","journal-title":"Mol Psychiatry"},{"issue":"8","key":"ioi220056r29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/DBP.0b013e3181e5ac93","article-title":"Use of antidepressants during pregnancy and risk of attention-deficit\/hyperactivity disorder in the offspring.","volume":"31","author":"Figueroa","year":"2010","journal-title":"J Dev Behav Pediatr"},{"issue":"4","key":"ioi220056r30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/ppe.2017.31.issue-4","article-title":"Antidepressant use in pregnancy and the risk of attention deficit with or without hyperactivity disorder in children.","volume":"31","author":"Boukhris","year":"2017","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"9","key":"ioi220056r31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003507","article-title":"In utero exposure to antidepressant drugs and risk of attention deficit hyperactivity disorder: a nationwide Danish cohort study.","volume":"3","author":"Laugesen","year":"2013","journal-title":"BMJ Open"},{"issue":"8108","key":"ioi220056r32","doi-asserted-by":"publisher","first-page":"j2350","DOI":"10.1136\/bmj.j2350","article-title":"Prenatal antidepressant use and risk of attention-deficit\/hyperactivity disorder in offspring: population based cohort study.","volume":"357","author":"Man","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"ioi220056r33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1067\/mpd.2003.139","article-title":"Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy.","volume":"142","author":"Casper","year":"2003","journal-title":"J Pediatr"},{"issue":"8","key":"ioi220056r34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.earlhumdev.2012.12.012","article-title":"Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.","volume":"89","author":"Hanley","year":"2013","journal-title":"Early Hum Dev"},{"issue":"8","key":"ioi220056r35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1023\/A:1025306304635","article-title":"Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics.","volume":"18","author":"Mortensen","year":"2003","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"ioi220056r36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jaac.2017.12.010","article-title":"Effect of time-dependent selective serotonin reuptake inhibitor antidepressants during pregnancy on behavioral, emotional, and social development in preschool-aged children.","volume":"57","author":"Lupattelli","year":"2018","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"ioi220056r37","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1157","article-title":"In utero antidepressants and neurodevelopmental outcomes in kindergarteners.","volume":"145","author":"Singal","year":"2020","journal-title":"Pediatrics"},{"issue":"3","key":"ioi220056r38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamapsychiatry.2021.3815","article-title":"Neurodevelopmental disorders among publicly or privately insured children in the United States.","volume":"79","author":"Straub","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"ioi220056r39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/EDE.0b013e31825fa230","article-title":"Sibling comparison designs: bias from non-shared confounders and measurement error.","volume":"23","author":"Frisell","year":"2012","journal-title":"Epidemiology"},{"issue":"5","key":"ioi220056r40","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/aje\/kwaa183","article-title":"Invited commentary: sibling-comparison designs, are they worth the effort?","volume":"190","author":"Frisell","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"4","key":"ioi220056r41","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/EDE.0000000000000649","article-title":"Confounders, mediators, or colliders: what types of shared covariates does a sibling comparison design control for?","volume":"28","author":"Sj\u00f6lander","year":"2017","journal-title":"Epidemiology"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2797101\/jamainternal_suarez_2022_oi_220056_1667324428.07615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T16:02:40Z","timestamp":1667836960000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2797101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2022.4268","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}